Mitsubishi UFJ Asset Management Co. Ltd. Grows Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Mitsubishi UFJ Asset Management increased its stake in IQVIA by 3.3% in Q4 to 353,057 shares (about 0.21% of the company) valued at roughly $79.57 million, while institutional investors collectively own about 89.62% of the stock.
• IQVIA beat Q earnings estimates (EPS $2.90 vs. $2.83) with revenue up 8.4% y/y, set FY2026 guidance of 12.650–12.950 EPS, and approved a $2.0 billion share repurchase program (up to 6.8% of shares).

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 353,057 shares of the medical research company's stock after acquiring an additional 11,250 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.21% of IQVIA worth $79,568,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in IQV. Brighton Jones LLC raised its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC raised its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock valued at $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at approximately $514,000. First Trust Advisors LP raised its stake in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company's stock valued at $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company's stock valued at $3,582,000 after purchasing an additional 1,155 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 1.4%

NYSE IQV opened at $178.95 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The stock has a market capitalization of $29.87 billion, a PE ratio of 22.17, a price-to-earnings-growth ratio of 1.75 and a beta of 1.18. The firm has a 50 day moving average of $170.14 and a two-hundred day moving average of $200.95.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to analysts' expectations of $4.10 billion. During the same quarter in the previous year, the business posted $2.70 EPS. The firm's revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IQV shares. Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $220.00 and set a "buy" rating for the company in a report on Friday, February 6th. Truist Financial dropped their price objective on shares of IQVIA from $290.00 to $245.00 and set a "buy" rating for the company in a report on Thursday, February 19th. Morgan Stanley set a $225.00 price objective on shares of IQVIA in a report on Thursday. Wall Street Zen upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a report on Sunday, April 19th. Finally, Citigroup dropped their price objective on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating for the company in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $225.69.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.